Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 338 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Is a Genomic Test Better at Finding Aggressive Prostate Cancer? October 13, 2022 FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma June 26, 2020 Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ March 16, 2021 Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... February 13, 2022 Load more HOT NEWS Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... A Cancer Revolution comes to Manchester: Patrick’s review Thinking outside the chromosome – how ecDNA is challenging conventional thinking
